Durvalumab 500mg/10ml solution for infusion vials
NHS hospitals in England used £136,776,937 of indicative cost of Durvalumab 500mg/10ml solution for infusion vials in the 12 months to July 2026, about 0.5% of all hospital medicines spend. That is up 44.3% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Durvalumab 500mg/10ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Durvalumab 500mg/10ml solution for infusion vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Clatterbridge Cancer Centre Nhs Ft | £11,111,796 |
| The Royal Marsden Nhs Foundation Trust | £6,547,230 |
| United Lincolnshire Hospitals Nhs Trust | £4,105,890 |
| Univ Hpl B/Ham Nhs Foundation Trust | £4,044,240 |
| The Christie Nhs Foundation Trust | £4,024,512 |
| Royal Surrey County Hosp Nhs Found Trust | £3,735,990 |
| Guy's & St Thomas' Nhs Foundation Trust | £3,689,136 |
| Imperial College Healthcare Nhs Trust | £3,403,080 |
| Nottingham University Hospitals Trust | £3,306,906 |
| Royal Free London Nhs Foundation Trust | £3,255,120 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.